Company intelligence / Profile preview

Neumentum, Inc.

Morristown, New Jersey, United States

Ownership: Private
Development stage: Phase 3

Overview

Neumentum is developing non-opioid pain management treatments. Their lead product NTM-001 (novel formulation of ketorolac) is in Phase 3 development with top-line results expected in 2024. NTM-006 has completed a positive Phase 2A clinical study in moderate to severe acute pain.

Therapeutic areas: Neurology
Modalities: Small moleculesNSAIDsNovel chemical entities
Industry: Biotech

Drug pipeline

4 assets

JNJ-10450232

3 more assets in the full pipeline.

Request access →

Partnerships

Nuance Biotech Co. Ltd (China)

Beyond the preview

Go deeper on Neumentum, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neumentum, Inc..

Explore the full profile